Video: IMRT for the Teal Stage of Prostate Cancer

Comment

Video: IMRT for the Teal Stage of Prostate Cancer

IMRT first came on the scene around 2004 and for the first time radiation therapy—beam radiation therapy—surpassed surgery as the preferred type of treatment.  Prior to that we had something called 3D conformal and it was somewhat effective, but unfortunately…

Comment

Prostate Digest | Fall 2018, Volume 22, Issue 3

Comment

Prostate Digest | Fall 2018, Volume 22, Issue 3

Hello Researcher, welcome to our fall issue of Prostate Digest. We recently held the 2018 Prostate Cancer Conference, and this issue has a summary of the event and information about how to get the event DVD. This issue contains four important articles covering new treatments and scans. The first highlights a recently FDA-approved oral medication called Earleada, which provided highly-effective therapy for men with hormone resistance. Our second articles reviews brachytherapy (seed implants) which are…

Comment

2018 Prostate Cancer Conference Recap

Comment

2018 Prostate Cancer Conference Recap

PCRI is grateful to everyone who attended our annual Prostate Cancer Conference, and we extend our thanks to all of the heroes who donate to ensure we can continue our mission. For those who were unable to attend, here is a recap of all of the wonderful information and events at the 2018 Prostate Cancer Conference. You can also order a DVD of the main sessions and Q+As at our website www.pcri.org

Comment

Advice for Your Doctor Visits

Comment

Advice for Your Doctor Visits

  1. Always obtain and keep copies of your medical records.

  2. Take things a step at a time and do your research. This is your life and your health, so you want to make the best decisions for yourself. Talk to your doctor about what you have researched, and don’t be afraid to do more research on treatments your doctor discusses with you.

Comment

Erleada: A New Treatment For Patients With Non-Metastatic Castrate Resistant Prostate Cancer

Comment

Erleada: A New Treatment For Patients With Non-Metastatic Castrate Resistant Prostate Cancer

In February 2018, the FDA approved Erleada for the treatment of prostate cancer. Erleada is an oral medicine approved for nonmetastatic, hormone-resistant disease. Men who have a rising PSA, low testosterone, and clear scans should begin Erleada immediately. Phase 3 SPARTAN clinical trial data showed that ERLEADA™ delays the  development of metastasis by over two years.

Comment

The Importance of Learning About All of Your Prostate Cancer Treatment Options

Comment

The Importance of Learning About All of Your Prostate Cancer Treatment Options

Over 160,000 men are diagnosed with prostate cancer in the United States each year. These men face the daunting task of choosing a treatment. Multiple options are available, but most men are not armed with the necessary information they need to make an informed decision. Both urologists and radiation oncologists offer several treatments and very often give patients conflicting information, further clouding the decision making process. Despite this, it is still critical that patients seek out physicians with…

Comment